Editing NMDA receptor (section)

==== Second generation derivative of memantine; nitromemantine ====
Several derivatives of Nitromemantine, a second-generation derivative of memantine, have been synthesized in order to perform a detailed [[structure activity relationship]] (SAR) of these novel drugs. One class, containing a nitro (NO<sub>2</sub>) group opposite to the bridgehead amine (NH<sub>2</sub>), showed a promising outcome. Nitromemantine utilizes memantine binding site on the NMDA receptor to target the NO<sub>x</sub> (X= 1 or 2) group for interaction with the S- nitrosylation/redox site external to the memantine binding site. Lengthening the side chains of memantine compensates for the worse drug affinity in the channel associated with the addition of the –ONO<sub>2</sub> group<ref name="Takahashi">{{cite journal | vauthors = Takahashi H, Xia P, Cui J, Talantova M, Bodhinathan K, Li W, Saleem S, Holland EA, Tong G, Piña-Crespo J, Zhang D, Nakanishi N, Larrick JW, McKercher SR, Nakamura T, Wang Y, Lipton SA | display-authors = 6 | title = Pharmacologically targeted NMDA receptor antagonism by NitroMemantine for cerebrovascular disease | journal = Scientific Reports | volume = 5 | pages = 14781 | date = October 2015 | pmid = 26477507 | pmc = 4609936 | doi = 10.1038/srep14781 | bibcode = 2015NatSR...514781T }}</ref>